Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-DA-23-036

Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity (R01 - Clinical Trial Not Allowed)

Closed on February 2, 2023.

Posted
November 8, 2022
Close date
February 2, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $798,591 in first-year total cost, median $798,591.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 SUY-N (A1)]1

Most frequent institutions

  1. UNIVERSITY OF CALIFORNIA, SAN FRANCISCO1
Competing awards under RFA-DA-23-036 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023The impact of early life opioid exposure on the molecular and functional trajectories of septal cell types1R01DA059388-01HARWELL, COREY CSTUBER, GARRET DUNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA$798,591ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
RFA-DA-23-036: Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity (R01 - Clinical Trial Not Allowed) | ScienceDex | ConductScience